SmartWatch from Smart Monitor Starts New Trial at NYU Langone Medical Center

SAN JOSE, Calif. - Dec. 2, 2014 - PRLog -- Smart Monitor is pleased to announce the start of clinical studies of SmartWatch at NYU’s Langone Medical Center. Researchers will study “Detecting Ictal Impairment using a simple task and a wrist worn device” in both inpatient and outpatient settings. This study is supported in part by grant funding from the Danny DID Foundation. This funding will make NYU the third epilepsy center currently participating in trials among children, teenagers, and adults at four sites across the United States.

One in 26 Americans will develop epilepsy during their lifetime, and one-third of people with epilepsy continue to have seizures despite treatment with medication, making alternative resources essential for their care and safety.

Developed by San Jose based Smart Monitor, SmartWatch® is a solution for the ongoing management of epilepsy and seizure related disorders. The solution fuses together wearable devices, mobile technology and cloud based analytics to maximize patient safety, and provide data to physicians (never available before in an outpatient setting) to optimize therapeutic regimens and enhance clinical outcomes. Alerts are sent within seconds after the onset of repetitive shaking motion allowing family and caregivers to institute timely intervention measures maximizing patient safety. Detailed episodic information, medication adherence, passive and active data is collected continuously and seamlessly on a secure HIPAA compliant server. SmartWatch maximizes patient engagement and enables physicians to more efficaciously manage chronic conditions such as epilepsy.

Trials are ongoing at Stanford University-an inpatient study focused on the device's ability to accurately detect seizures and record them into an online epilepsy diary-and the University of Virginia, where an outpatient study examines whether the SmartWatch can help to reduce anxiety among teens and their parents. Additional trials are expected to begin at Boston Children's Hospital in early 2015.

"We are proud to continue this partnership with the Danny Did Foundation for a series of important studies that stand to change the lives of millions of people affected by epilepsy," says Anoo Nathan, CEO of Smart Monitor. "Through this grant, we have the unique opportunity within these four venues to research and collect data on different aspects of epilepsy, demonstrate the value of our SmartWatch and ultimately optimize ongoing clinical and therapeutic care." “It is a goal of Danny’s cause to grow the awareness and use of devices and technology that can help to enable early intervention when seizure activity occurs,” says Tom Stanton, Executive Director of the Danny Did Foundation. “Gathering data from clinical settings is a key step in giving doctors and parents the comfort level to know that a device is effective. We’re excited to continue this research in a epilepsy center as respected as NYU.”

The SmartWatchÒ won the 2014 Health Innovation Award at the Consumer Electronics Show (CES), and has been selected as a finalist again for CES 2015 for Chronic Condition Management.

About Smart Monitor - Smart Monitor empowers and engages patients and care providers to better manage complex chronic health conditions. Headquartered in San Jose, California, Smart Monitor fuses together sensor, mobile, and cloud technologies with big data analytics in a seamless environment for optimizing care and outcomes. Smart Monitor’s patent-protected solutions foster autonomy and enhance safety for people with chronic health conditions, while offering significant peace of mind to their families and care providers. For more information, visit www.smart-monitor.com.

About Danny Did Foundation - Founded by Chicagoans Mike and Mariann Stanton in January 2010 after the sudden death of their four-year-old son Danny, the Danny Did Foundation’s primary mission is to prevent deaths caused by seizures.  The Foundation is dedicated to advancing public awareness of Sudden Unexpected Death in Epilepsy (SUDEP), enhancing the SUDEP communication model between medical professionals and families impacted by seizures, and gaining mainstream acceptance and use of seizure detection and prediction devices that may assist in preventing seizure-related deaths. Epilepsy affects nearly 3 million people in the United States and 65 million people worldwide. One in 26 Americans will develop epilepsy during their lifetime. Seizures can be fatal—more people die as a result of seizures than from fires and sudden infant death syndrome (SIDS) combined—and thousands of deaths occur annually from SUDEP, status epilepticus (prolonged seizures), and other seizure-related causes such as drowning and other accidents. The name of the Danny Did Foundation originates from the last line of Danny Stanton’s obituary, written by his dad: “Please go and enjoy your life. Danny did.”